Free Trial
NASDAQ:FENC

Adherex Technologies Q2 2025 Earnings Report

Adherex Technologies logo
$9.11 -0.13 (-1.41%)
Closing price 08/13/2025 04:00 PM Eastern
Extended Trading
$9.10 -0.01 (-0.11%)
As of 08/13/2025 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Upcoming Event
Earnings Conference Call
Adherex Technologies Q2 2025
00:00 / 00:00
Live Transcript
Follow Audio

Adherex Technologies EPS Results

Actual EPS
N/A
Consensus EPS
-$0.06
Beat/Miss
N/A
One Year Ago EPS
N/A

Adherex Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
$9.52 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Adherex Technologies Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Adherex Technologies Earnings Headlines

Adherex Technologies (NASDAQ:FENC) Cut to Hold at Wall Street Zen
New law could create $3.7 trillion tsunami.
During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard. The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.” Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%.
Adherex Technologies (FENC) to Release Earnings on Tuesday
Adherex Technologies (NASDAQ:FENC) Trading Up 6.1% - Time to Buy?
See More Adherex Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Adherex Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adherex Technologies and other key companies, straight to your email.

About Adherex Technologies

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies (NASDAQ:FENC) and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

View Adherex Technologies Profile

More Earnings Resources from MarketBeat